Science Corp raises $230M as it races to bring its brain implant to market

Science Corp has raised $230M in Series C funding to advance its brain-computer interface, PRIMA, aimed at restoring vision for those with macular degeneration. With a post-money valuation of $1.5B, the startup plans to seek regulatory approval in the EU, targeting a mid-2026 launch. The funding will also support a broader research portfolio, including organ preservation technologies.

Key Points

• Science Corp raised $230M in Series C funding, pushing its valuation to $1.5B.
• PRIMA is a tiny chip that restores vision for patients with advanced macular degeneration.
• Science Corp acquired PRIMA's assets from Pixium Vision in 2024 and enhanced it.
• In trials with 47 patients, 80% showed improvement in visual acuity.
• The company aims for regulatory approval in the EU by mid-2026 for a market launch.
• Funding will also support research in biohybrid neural interfaces and a new organ preservation platform.

Relevance

• The rise of brain-computer interfaces (BCIs) mirrors trends in neurotechnology and AI integration.
• Historically, medical technology advancements often follow significant funding rounds.
• Rising interest in neurotechnology aligns with legislative and regulatory shifts around medical devices.
• By 2025, the integration of more advanced personal health technologies is expected to grow.

Science Corp's significant funding indicates a pivotal moment for advancing neurotechnology, particularly in vision restoration. With regulatory approval on the horizon, it is set to potentially lead the BCI market by 2026, marking a crucial step in innovative health tech solutions.